Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. Revance Therapeutics, Inc. executed the pricing of $250.0 million…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now